AIROS Medical, a leading medical technology manufacturer specializing in compression therapy solutions for lymphedema and venous disorders, today announced a longer warranty for its line of pneumatic sequential compression devices. The AIROS 6P and AIROS 8P sequential compression devices now have a five-year warranty. The previous warranty for these devices was three years. All devices […]
New Omnilert report highlights encouraging shifts in key indicators while emphasizing layered security and rapid response Omnilert, a national leader in AI-powered safety and emergency communications, has released its 2025 Gun Violence Statistics, along with a new interactive infographic examining national and school-related gun violence trends. In 2025, the U.S. recorded 38,762 gun-violence deaths, highlighting
Quantix, North America’s leading supply chain services company to the chemical industry, today announced new strategic partnerships with MC Tank Lines and Leahy Transport, strengthening its transportation network and expanding capabilities across North America. These partnerships align with Quantix’s ongoing strategy to collaborate with best-in-class carriers that share their commitment to safety, reliability, and operational
Six months in, the Elevate practicum program and a partnership with University of Nevada, Reno are catalysts for industry change Centria Autism, a national provider of therapeutic services for children with autism and their families, continues to make strides in developing aspiring clinicians and closing the gap of BCBAs. The BCBA shortage is nothing new–the
(NASDAQ:SDM), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Smart Digital To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Smart Digital between May 5, 2025 and September 26, 2025 at 9:34 AM EST and would like to discuss your legal
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Smart Digital GlobeNewswire January 14, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Smart Digital To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Smart Digital between
(OtherOTC:EGRX),(OTC US:EGRX), WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment of Postoperative Nausea and Vomiting (PONV) alone or
(NasdaqGM:AQST), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics GlobeNewswire January 14, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Aquestive Therapeutics stock
Eagle Pharmaceuticals Announces Divestiture of Barhemsys GlobeNewswire January 14, 2026 WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France. Barhemsys is used for the treatment